CN114451455A - Breast milk oligosaccharide composition for improving intestinal microenvironment health - Google Patents
Breast milk oligosaccharide composition for improving intestinal microenvironment health Download PDFInfo
- Publication number
- CN114451455A CN114451455A CN202111453451.7A CN202111453451A CN114451455A CN 114451455 A CN114451455 A CN 114451455A CN 202111453451 A CN202111453451 A CN 202111453451A CN 114451455 A CN114451455 A CN 114451455A
- Authority
- CN
- China
- Prior art keywords
- milk
- powder
- sialyllactose
- fucosyllactose
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 44
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 39
- 235000020256 human milk Nutrition 0.000 title claims abstract description 38
- 210000004251 human milk Anatomy 0.000 title claims abstract description 38
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 28
- 230000036541 health Effects 0.000 title claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 35
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims abstract description 31
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims abstract description 27
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims abstract description 27
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims abstract description 27
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940062827 2'-fucosyllactose Drugs 0.000 claims abstract description 24
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 235000013305 food Nutrition 0.000 claims abstract description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 15
- 229930195729 fatty acid Natural products 0.000 claims abstract description 15
- 239000000194 fatty acid Substances 0.000 claims abstract description 15
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 15
- 230000009286 beneficial effect Effects 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims abstract 10
- 235000013336 milk Nutrition 0.000 claims description 29
- 239000008267 milk Substances 0.000 claims description 29
- 210000004080 milk Anatomy 0.000 claims description 29
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims description 24
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 24
- 235000013350 formula milk Nutrition 0.000 claims description 21
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 21
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 20
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 19
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 10
- 235000015872 dietary supplement Nutrition 0.000 claims description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 210000004921 distal colon Anatomy 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 235000011054 acetic acid Nutrition 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 235000013406 prebiotics Nutrition 0.000 claims description 2
- 235000008452 baby food Nutrition 0.000 abstract description 2
- 230000007413 intestinal health Effects 0.000 abstract description 2
- 238000000855 fermentation Methods 0.000 description 33
- 230000004151 fermentation Effects 0.000 description 33
- 238000004977 Hueckel calculation Methods 0.000 description 28
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 22
- SNFSYLYCDAVZGP-OLAZETNGSA-N 2'-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@H](O)[C@@H]1O SNFSYLYCDAVZGP-OLAZETNGSA-N 0.000 description 16
- 210000003608 fece Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 239000007789 gas Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 8
- 239000000178 monomer Substances 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- -1 fucosyl oligosaccharide Chemical class 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- AXQLFFDZXPOFPO-FSGZUBPKSA-N beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO AXQLFFDZXPOFPO-FSGZUBPKSA-N 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 2
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 125000005630 sialyl group Chemical group 0.000 description 2
- 150000004043 trisaccharides Chemical group 0.000 description 2
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- PNIWLNAGKUGXDO-UHFFFAOYSA-N Lactosamine Natural products OC1C(N)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 PNIWLNAGKUGXDO-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102400001107 Secretory component Human genes 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- DOVBXGDYENZJBJ-ONMPCKGSSA-N lactosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DOVBXGDYENZJBJ-ONMPCKGSSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/203—Dietetic milk products not covered by groups A23C9/12 - A23C9/18 containing bifidus-active substances, e.g. lactulose; containing oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention provides breast milk oligosaccharide compositions that improve gut microenvironment health. Specifically, the invention provides an application of a breast milk oligosaccharide composition in preparing a food for improving intestinal microenvironment health, wherein the breast milk oligosaccharide composition comprises 2 '-fucosyllactose and 3' -sialyllactose, and the mass ratio of the 2 '-fucosyllactose to the 3' -sialyllactose is (3-8): 1; the improving gut microenvironment health comprises inhibiting or reducing production of gut branched chain fatty acids. The breast milk oligosaccharide composition can be added into infant food, and is beneficial to improving the intestinal health of infants fed by formula powder.
Description
Technical Field
The invention relates to a breast milk oligosaccharide composition and application thereof, in particular to a breast milk oligosaccharide composition containing 2 '-fucosyllactose and 3' -sialyllactose in a specific ratio and new application thereof in improving the intestinal microenvironment health, particularly inhibiting or reducing the generation of intestinal isovaleric acid.
Background
Breast Milk Oligosaccharides (HMOs) belong to the third most abundant substances in breast Milk, except lactose and fat. The total content varies at various stages of lactation, and is about 12-14g/L in mature milk and about 20-24g/L in colostrum. Each breast milk oligosaccharide has a lactose at the reducing end, mostly with poly lactosamine as the structural backbone, and fucose, sialic acid, or both at the chain end. Breast milk oligosaccharides are mainly composed of three major groups: (1) fucosyl oligosaccharide, which is a representative substance of 2 '-fucosyl oligosaccharide and 3' -fucosyl oligosaccharide; (2) sialic acid-based oligosaccharides, including 3 '-sialyllactose and 6' -sialyllactose as representative substances; (3) oligosaccharides formed by a core sugar chain structure containing no fucosyl or sialyl group are typified by lacto-N-tetraose and lacto-N-neotetraose. HMOs are present in individual differences in content and are associated with the lewis secretory component of the nursing mother. Since the raw material of infant formula is usually cow's milk, which usually contains no or very little such oligosaccharides, HMOs constitute a gap that infant formula is expected to approach the breast milk.
The intestinal flora is an important constituent substance of a human intestinal microecosystem and plays an important role in human health. Anaerobic bacilli, bifidobacteria, eubacteria, streptococcus, lactobacillus and the like in the intestinal flora can release metabolites such as Short Chain Fatty Acids (SCFA) mainly comprising acetic acid, propionic acid, butyric acid and the like by fermenting carbohydrates, proteins, lipids and the like. SCFA can regulate various physiological functions of the body and play an important role in regulating the health of the intestinal microenvironment. For example, SCFA provide energy and regulate electrolytes, acetate is a significant source of host energy, propionate is involved in the reversal of pyruvate to glucose, and butyrate is taken up by epithelial cells and is the primary energy source for epithelial cells. SCFA also have anti-inflammatory, intestinal barrier function enhancing and antibacterial effects. The SCFA released by the intestinal flora fermentation can reduce the pH value of the intestinal tract, thereby increasing the growth of beneficial bacteria in the intestinal tract and reducing the proliferation of harmful bacteria.
In addition, the intestinal metabolites may also have small amounts of Branched Chain Fatty Acids (BCFAs) such as isobutyric acid and isovaleric acid, which are produced by the intestinal flora metabolizing branched chain amino acids such as valine, leucine and isoleucine, etc., as products of bacterial fermentation of undigested proteins and polypeptides upon arrival in the colon, primarily from shedding of dietary or mucosal cells. Isobutyric acid and isovaleric acid are thus metabolites of proteins, unlike acetic, propionic, and butyric acids. The reduction of isobutyric acid and isovaleric acid, which can be seen as a shift from protein fermentation to fiber fermentation, is considered a positive effect. These branched-chain fatty acids are considered marker substances for colonic protein fermentation, and this process also produces other metabolites, such as ammonia, phenol, p-cresol, or biogenic amines, which can cause damage to cells in the small intestine environment (Aguirre et al, 2016). High levels of isovaleric acid in stool are associated with depression and cortisol levels in humans (szczelsnik et al, 2016).
The feces of infants not receiving breast feeding have higher contents of branched chain fatty acids isobutyric acid and isovaleric acid than those of infants fed breast feeding, the higher branched chain fatty acids are from amino acid metabolism, and the higher short chain fatty acids may have an effect on infant metabolism. Some studies have shown that isobutyric acid, isovaleric acid, both volatile fatty acids, regulate serotonin biosynthesis and are associated with several pathological physiological states, in particular isovaleric acid, although only a very small fraction of the total fatty acid metabolites, but high levels of isovaleric acid are toxic and associated with visceral pain and other gastrointestinal disorders such as irritable bowel syndrome following infection.
Therefore, for infants who are not receiving breast feeding, there is a need for solutions that improve gut microenvironment health, such as reducing branched chain fatty acids such as isobutyric acid and isovaleric acid.
Disclosure of Invention
The invention finds that some breast milk oligosaccharide compositions have the effect of remarkably improving the intestinal microenvironment health, particularly can inhibit or reduce the generation of intestinal branch chain fatty acids, and particularly can remarkably reduce the generation of intestinal branch chain fatty acids such as isovaleric acid for infants (formula powder fed infants) which are not subjected to breast feeding, thereby providing a breast milk oligosaccharide composition and application thereof.
Specifically, the invention provides an application of a breast milk oligosaccharide composition in preparing a food for improving intestinal microenvironment health, wherein the breast milk oligosaccharide composition comprises 2 '-fucosyllactose and 3' -sialyllactose, and the mass ratio of the 2 '-fucosyllactose to the 3' -sialyllactose is (3-8): 1; the improving gut microenvironment health comprises inhibiting or reducing the production of gut branched chain fatty acids.
It is known that human milk oligosaccharides include fucosyllactose, sialyllactose, and the basic sugar chain structure of human milk oligosaccharides without fucosyl or sialyl groups (typical representatives include 3' -sialyllactose and its isomer lacto-N-neotetraose).
Wherein 2 ' -fucosyllactose (2 ' -fucosyllactose, 2 ' -FL or 2FL) is a trisaccharide structure formed by fucose and lactose, and is a representative substance of fucosyl oligosaccharide. Commercially available materials are usually prepared by microbial fermentation and have the same structure as oligosaccharides found in human milk.
3 ' -sialyllactose (3 ' -sialyllactose, 3 ' -SL or 3SL) is a trisaccharide structure formed by sialic acid and lactose, and is a representative substance of sialyl oligosaccharides. Commercially available materials are usually prepared by microbial fermentation and have the same structure as oligosaccharides found in human milk.
According to a particular embodiment of the invention, the use of a breast milk oligosaccharide composition of the invention in the preparation of a food product for improving gut microenvironment health in a formula-fed infant.
According to a particular embodiment of the invention, the use of a breast milk oligosaccharide composition of the invention in the preparation of a food product for improving gut microenvironment health, said reduction of gut branched chain fatty acids comprising reducing distal colon isovalerate production.
According to a particular embodiment of the invention, the use of a breast milk oligosaccharide composition of the invention in the preparation of a food product for improving gut microenvironment health further comprising: reduce production of distal colon isobutyric acid, lower intestinal pH, be utilized by the gut flora as a prebiotic in the gut system and produce gas, and/or regulate production of beneficial short chain fatty acids including formic acid, acetic acid, propionic acid, butyric acid and/or lactic acid in the gut system.
On the other hand, the invention also provides a breast milk oligosaccharide composition, which comprises the following components in percentage by mass (3-8): 1 of 2 '-fucosyllactose and 3' -sialyllactose. The breast milk oligosaccharide composition can be used for improving intestinal microenvironment health.
In some embodiments of the present invention, the present invention further provides a food, wherein the food comprises breast milk oligosaccharide 2 '-fucosyllactose and 3' -sialyllactose, and the mass ratio of the 2 '-fucosyllactose to the 3' -sialyllactose is (3-8): 1.
in some embodiments of the invention, the breast milk oligosaccharide composition of the invention comprises a mixture of 3:1 of 2 '-fucosyllactose and 3' -sialyllactose.
In some embodiments of the invention, the breast milk oligosaccharide composition of the invention comprises a mixture of 8:1 of 2 '-fucosyllactose and 3' -sialyllactose.
According to specific embodiments of the invention, the food for improving gut microenvironment health of the subject invention comprises one or more of a nutritional supplement, infant formula powder (infant formula), liquid milk, a dietary supplement.
In some embodiments of the invention, the food product for improving gut microenvironment health of the subject invention is a nutritional supplement and the 2 '-fucosyllactose and 3' -sialyllactose are applied in the nutritional supplement in an amount of 1.0-50g per 100g of powder. The nutritional supplement may be designed specifically for formula-fed infants to improve their intestinal microenvironment health.
In some embodiments of the invention, the food product for improving gut microenvironment health of the subject invention is an infant formula, the 2' -fucosyllactose is applied to the infant formula in an amount of: the application amount in the milk powder is 14.2-3182.2mg/100g powder, or 0.02-4.2g/L calculated by conversion into milk; preferably, the application amount in the milk powder is 70.9-1818.4mg/100g powder, or 0.1-2.4g/L converted into milk; more preferably, the amount of the powder used in the milk powder is 70.9-1515.3mg/100g of powder, or 0.1-2.0g/L in terms of milk. In addition, the amount of 3' -sialyllactose is used with reference to the aforementioned ratio. In particular, the amount of 3' -sialyllactose used in the infant formula was: the application amount in the milk powder is 14.2-1515.3mg/100g powder, or 0.02-2.0g/L calculated by conversion into milk; preferably, the application amount in the milk powder is 70.9-454.6mg/100g powder, or 0.1-0.6g/L in terms of conversion to milk; more preferably, the amount of the milk powder is 70.9-227.3mg/100g powder, or 0.1-0.3g/L in terms of milk.
The application amount of each breast milk oligosaccharide in other foods can be properly adjusted according to specific needs.
In conclusion, the invention finds that some breast milk oligosaccharide compositions can obviously improve intestinal microenvironment health, can be added into infant food (including infant formula powder, liquid milk, complementary food and nutritional supplements) and are beneficial to improving the intestinal health of infants fed by the formula powder.
Drawings
FIG. 1 shows the fermentation of 2 '-FL and 3' -SL compositions of the invention with infant feces to produce isovaleric acid.
Fig. 2 shows the pH profile of each HMO monomer and composition after fermentation of infant feces.
Fig. 3 shows the barometric pressure profile of various HMO monomers and compositions after fermentation with infant feces.
FIG. 4 shows the short chain fatty acid production of each HMO monomer and composition of the invention.
Fig. 5 shows the fermentation of various HMO monomers and compositions of the present invention with infant feces to produce formic, acetic, propionic, butyric, isobutyric, lactic acids.
Detailed Description
For a more clear understanding of the technical features, objects and advantages of the present invention, reference is now made to the following detailed description taken in conjunction with the accompanying specific embodiments, and the technical solutions of the present invention are described, it being understood that these examples are intended to illustrate the present invention and are not intended to limit the scope of the present invention.
In the examples, each raw reagent material is commercially available, and the experimental method not specifying the specific conditions is a conventional method and a conventional condition well known in the art, or a condition recommended by an instrument manufacturer.
In addition, general procedures required to be followed in the experiments in each example, such as inoculation culture of fecal bacteria, and the like, are listed below in order to avoid repetition.
Experimental methods
Samples of infant feces were obtained from donors (all subjects infants were three months old infants fed regular infant formula) and stored frozen. The fecal sample is thawed within 30 minutes, gently mixed with the culture medium, added to the batch fermentation medium as the initial culture material, and the solution is continuously mixed to maintain the desired degree of mixing uniformity. Because the thawing time was consistent, the initial bacterial composition was similar for each group. The short chain fatty acids, pH, air pressure and flora during fermentation were measured. All HMO feeds in this experiment were from the supplier Jennewein. The specific experimental process is as follows:
sample pretreatment
Feces were collected from infant feces donors multiple times through diapers. Each stool collected was transferred to a test tube and stored at-20 ℃. The feces samples collected several times were thawed and mixed, and diluted and dissolved (gas phase: 81% N) using a sterilized sodium chloride solution (0.9% (w/v)) in an anaerobic bench2、15％CO2And 4% of H2Bactron300, Sheldon Manufacturing, Cornelius, USA). The mixture was mixed by adding sterilized glass beads and thoroughly mixed (2000 rpm). The fecal solution was incubated with SIEM medium at 5: 82(v/v) as a fecal culture medium.
Small batch fermentation
10mL of infant fecal flora was taken and transferred to a fermentation flask for small batch fermentation under anaerobic conditions. Each flask also contained 20mL pbs buffer (for dissolution and entrainment of HMO test substance) supplemented with a different set of HMO monomers or compositions, based on 43mL of base buffer (to adjust pH and simulate the corresponding distal colon environment), with a final concentration of 2g/L of each HMO monomer or composition in each flask. The control group was not added HMO. The vials were incubated at 37 ℃ with shaking. During the incubation, the gas pressure was measured at 0, 6, 24 and 48 hours (the pressure in the fermentation flask was measured using a gas pressure gauge), followed by sampling to detect pH and short chain fatty acids. The assay was repeated three times.
The method for measuring the short-chain fatty acid comprises the following steps: short chain fatty acids in the samples were determined using a gas chromatograph GC-2014(Shimadzu,'s-Hertogenbosch, Netherlands). After separation of each fatty acid in the sample by capillary column (EC-1000, Econo-Cap,25 mm. times.0.53 mm, 1.2. mu.M, Alltech, Laarne, Belgium), detection was performed using a flame ionization detector with the injector temperature set at 100 ℃, the detector temperature set at 220 ℃, nitrogen as a carrier gas, and 2-methylacetic acid as an internal standard.
During HMO intervention, the gas production of each group was compared by measuring the pressure change. Analysis of short chain fatty acids included isovaleric acid, as well as formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid and lactic acid, each of which was analyzed by HPLC.
Data analysis
Statistical analysis of Two way ANOVA was performed on the data results and significant difference analysis was performed using Tukey's multiple complexes test. Two groups were marked with an asterisk if they were significantly different and p < 0.05. Two asterisks indicate p < 0.01. Three asterisks indicate p < 0.001.
Example 1: 2 '-FL and 3' -SL composition for inhibiting/reducing generation of isovaleric acid
Experimental groups were as follows: in the experiments of each example, a plurality of groups of test groups were set, and the addition of HMO in each group was as follows (except for the control group, which had no HMO added, the total final concentration of HMO in each of the remaining fermentation flasks was 2 g/L):
control group: no HMO added (i.e. buffer only);
test group 1: adding 2 '-FL and 3' -SL compositions, wherein the mass ratio of 2 '-FL to 3' -SL is 3: 1;
test group 2: adding 2 '-FL and 3' -SL compositions, wherein the mass ratio of 2 '-FL to 3' -SL is 8: 1;
comparative group 1: addition of 2' -FL only;
comparative group 2: addition of 3' -SL only;
comparative group 3: adding an LNT and 3 '-SL composition, wherein the mass ratio of the LNT to the 3' -SL is 6: 1.
the isovaleric acid production at 0, 6, 24 and 48 hours for each test group is shown in FIG. 1 and Table 1.
TABLE 1
| After fermentation for 48h, isovaleric acid is produced | Whether there is a significant difference | P value |
| 2’-FL+3’-SL 3:1vs.3’-SL | * | 0.0324 |
| 2 '-FL + 3' -SL 3:1vs. control | ** | 0.01 |
| 2’-FL+3’-SL 8:1vs.3’-SL | * | 0.0241 |
| 2 '-FL + 3' -SL 8:1vs. control | * | 0.0127 |
| LNT + 3' -SL 6:1vs. control | Whether or not | 0.3023 |
| 2' -FL vs. control | * | 0.0292 |
| 3' -SL vs. control | * | 0.0342 |
After 48 hours of fermentation, the production of isovaleric acid was analyzed and the tendency of each HMO composition or monomer to reduce isovaleric acid compared to the control was found. Both 2 '-FL and 3' -SL alone significantly reduced isovaleric acid (P <0.05), while the mass ratio 3: the 2 '-FL + 3' -SL composition of the 1 reduces the isovaleric acid (P <0.01) more obviously, and embodies the synergistic effect of the composition. The mass ratio is 8: the 2 '-FL + 3' -SL composition of 1 also significantly reduced isovaleric acid (P < 0.05). And the mass ratio is 3:1 and 8: the 2 ' -FL +3 ' -SL composition of 1 reduced isovaleric acid to a greater extent than 3 ' -SL alone (P < 0.05).
Example 2: influence of 2 '-FL and 3' -SL composition on fermentation gas production and other acidic property production of intestinal flora
In this example, the effect of the 2 '-FL and 3' -SL composition on the fermentation and gas production of the intestinal flora and the production of other acidic properties was examined. Wherein, the following test groups are set, and the addition of HMO in each group is as follows (except that HMO is not added in a control group, the total final concentration of HMO in each fermentation bottle is 2 g/L):
control group: no HMO added (i.e. buffer only);
test group 1: adding 2 '-FL and 3' -SL compositions, wherein the mass ratio of 2 '-FL to 3' -SL is 3: 1;
test group 2: adding 2 '-FL and 3' -SL compositions, wherein the mass ratio of 2 '-FL to 3' -SL is 8: 1;
comparative group 1: addition of 2' -FL only;
comparative group 2: only 3' -SL was added.
pH of HMO composition after fermentation with infant feces
The pH of the infant feces fermented to produce pH in each test group is shown in FIG. 2. Almost all HMOs and HMO compositions tested had similar effects on acidification (i.e. lowering pH) of the medium. Whereas the 3' -SL fermentation capacity or the capacity to produce short-chain fatty acids as metabolites is not to be expected to be strong. According to the invention, 2 ' -FL and 3 ' -SL are combined, so that the capability of 3 ' -SL in promoting intestinal flora fermentation and reducing pH can be remarkably improved.
Air pressure conditions of HMO composition after fermentation with infant feces
The air pressure after fermentation of the infant feces in each test group is shown in fig. 3. Each test group has certain fermentation gas production capacity, and the 3' -SL fermentation and gas pressure production capacity is relatively weak. According to the invention, after the 2 ' -FL and the 3 ' -SL are combined, the capability of the 3 ' -SL in promoting the fermentation and gas production of intestinal flora can be obviously improved.
Cases where HMO compositions produce short chain fatty acids after fermentation of infant faeces
The production of short chain fatty acids by the HMO compositions of each group after fermentation of infant faeces is shown in fig. 4 and 5, respectively. It can be seen that each of the subject groups of the 2 '-FL and 3' -SL compositions of the present invention are capable of promoting the production of beneficial short chain fatty acids, including formic, acetic, propionic, butyric and/or lactic acids, to some extent, and reducing the production of isobutyric acid.
Example 3 infant formula with added breast milk oligosaccharide combination
The embodiment provides an infant formula milk powder with the age of 0-6 months, wherein the formula milk powder contains 11.1g/100g of total protein, 28.3g/100g of fat, 52.9g/100g of carbohydrate and 1.4g/100g of breast milk oligosaccharide, the breast milk oligosaccharide is a combination of 2 '-fucosyllactose (2' -FL) and 3 '-sialyllactose (3' -SL), and the mass ratio of the 2 '-fucosyllactose (2' -FL) to the 3 '-sialyllactose (3' -SL) is 3: 1.
Claims (10)
1. the application of a breast milk oligosaccharide composition in preparing a food for improving intestinal microenvironment health is disclosed, wherein the breast milk oligosaccharide composition comprises 2 '-fucosyllactose and 3' -sialyllactose, and the mass ratio of the 2 '-fucosyllactose to the 3' -sialyllactose is (3-8): 1; the improving gut microenvironment health comprises inhibiting or reducing the production of gut branched chain fatty acids.
2. The use of claim 1, wherein the food product is for improving the gut microenvironment health of formula-fed infants and young children.
3. The use of claim 1 or 2, wherein the reduction of intestinal branched chain fatty acids comprises a reduction in distal colon isovalerate production.
4. The use of claim 1, wherein the improving intestinal microenvironment health further comprises: reduce production of distal colon isobutyric acid, lower intestinal pH, be utilized by the gut flora as a prebiotic in the gut system and produce gas, and/or regulate production of beneficial short chain fatty acids including formic acid, acetic acid, propionic acid, butyric acid and/or lactic acid in the gut system.
5. Use according to claim 1, wherein the food product comprises one or more of a nutritional supplement, infant formula, liquid milk, a complementary food.
6. Use according to claim 5, wherein the food product is a nutritional supplement and the 2 '-fucosyllactose and 3' -sialyllactose are used in the nutritional supplement in an amount of 1.0-50g per 100g of powder.
7. Use according to claim 5, wherein the food product is an infant formula and the 2' -fucosyllactose is applied in the infant formula in an amount of: the application amount in the milk powder is 14.2-3182.2mg/100g powder, or 0.02-4.2g/L calculated by conversion into milk; preferably, the application amount in the milk powder is 70.9-1818.4mg/100g powder, or 0.1-2.4g/L converted into milk; more preferably, the amount of the powder used in the milk powder is 70.9-1515.3mg/100g of powder, or 0.1-2.0g/L in terms of milk.
8. Use according to claim 7, wherein the 3' -sialyllactose is used in the infant formula in an amount of: the application amount in the milk powder is 14.2-1515.3mg/100g powder, or 0.02-2.0g/L calculated by conversion into milk; preferably, the application amount in the milk powder is 70.9-454.6mg/100g powder, or 0.1-0.6g/L in terms of conversion to milk; more preferably, the amount of the milk powder is 70.9-227.3mg/100g powder, or 0.1-0.3g/L in terms of milk.
9. A breast milk oligosaccharide composition comprises 2 '-fucosyllactose and 3' -sialyllactose, wherein the mass ratio of the 2 '-fucosyllactose to the 3' -sialyllactose is (3-8): 1.
10. a food comprises breast milk oligosaccharide 2 '-fucosyllactose and 3' -sialyllactose, wherein the mass ratio of the 2 '-fucosyllactose to the 3' -sialyllactose is (3-8): 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111453451.7A CN114451455A (en) | 2021-11-30 | 2021-11-30 | Breast milk oligosaccharide composition for improving intestinal microenvironment health |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111453451.7A CN114451455A (en) | 2021-11-30 | 2021-11-30 | Breast milk oligosaccharide composition for improving intestinal microenvironment health |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114451455A true CN114451455A (en) | 2022-05-10 |
Family
ID=81406064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111453451.7A Pending CN114451455A (en) | 2021-11-30 | 2021-11-30 | Breast milk oligosaccharide composition for improving intestinal microenvironment health |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114451455A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117137925A (en) * | 2023-10-07 | 2023-12-01 | 广州菲勒生物科技有限公司 | Nutritional preparation for preventing respiratory tract virus infection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110839702A (en) * | 2018-08-21 | 2020-02-28 | 内蒙古伊利实业集团股份有限公司 | Breast milk oligosaccharide composition for improving abundance of infant intestinal flora and feces smell and application thereof |
| CN112514997A (en) * | 2020-11-30 | 2021-03-19 | 内蒙古伊利实业集团股份有限公司 | Breast milk oligosaccharide for improving intestinal microenvironment health and application thereof |
| CN112868800A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof |
-
2021
- 2021-11-30 CN CN202111453451.7A patent/CN114451455A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110839702A (en) * | 2018-08-21 | 2020-02-28 | 内蒙古伊利实业集团股份有限公司 | Breast milk oligosaccharide composition for improving abundance of infant intestinal flora and feces smell and application thereof |
| CN112868800A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof |
| CN112514997A (en) * | 2020-11-30 | 2021-03-19 | 内蒙古伊利实业集团股份有限公司 | Breast milk oligosaccharide for improving intestinal microenvironment health and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117137925A (en) * | 2023-10-07 | 2023-12-01 | 广州菲勒生物科技有限公司 | Nutritional preparation for preventing respiratory tract virus infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112514997B (en) | Breast milk oligosaccharide for improving intestinal microenvironment health and application thereof | |
| JP2021063079A (en) | Glycan therapeutics and related methods thereof | |
| EP3209308B1 (en) | Activated bifidobacteria and methods of use thereof | |
| EP2117355B1 (en) | Method of improving skills with a composition comprising non-digestible saccharide | |
| CN111838683A (en) | Prebiotic composition containing human milk oligosaccharide and application thereof | |
| JP2022506276A (en) | Oligosaccharide preparations and compositions | |
| WO2006130205A1 (en) | Use of polydextrose for simulating the functional attributes of human milk oligosaccharides in formula-fed infants | |
| US20050288250A1 (en) | Novel use of carbohydrates and compositions | |
| US20230330131A1 (en) | Prebiotic composition and its use | |
| JP2007507214A (en) | Analysis of prebiotic effects | |
| CN113519849A (en) | Breast milk oligosaccharide for improving intestinal tract resistance to escherichia coli infection and application thereof | |
| Musilova et al. | Prebiotic effects of a novel combination of galactooligosaccharides and maltodextrins | |
| Chierici et al. | Advances in the modulation of the microbial ecology of the gut in early infancy | |
| CN114451455A (en) | Breast milk oligosaccharide composition for improving intestinal microenvironment health | |
| CN114208893A (en) | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof | |
| Le Blay et al. | Set up of a new in vitro model to study dietary fructans fermentation in formula-fed babies | |
| CN114145353A (en) | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof | |
| CN114451454A (en) | Breast milk oligosaccharide composition for improving intestinal microenvironment health | |
| JP7396798B2 (en) | Composition for promoting intestinal butyrate production | |
| Rastall | Galacto‐oligosaccharides as prebiotic food ingredients | |
| CN114568504A (en) | Breast milk oligosaccharide for regulating butyric acid and improving intestinal microenvironment health and application thereof | |
| RU2808430C2 (en) | Prebiotic composition and its use | |
| CN117070425B (en) | Technological method for improving metabolic stability of probiotics in organism and probiotics freeze-dried powder | |
| WO2022091736A1 (en) | Composition for improving intestinal bacterial flora and composition for suppressing production of substances by intestinal putrefaction | |
| US11896043B2 (en) | Intestinal immune-enhancing agent, food product, and medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |